If youre currently on tirzepatide or another GLP-1 medication like Ozempic or Wegovy (semaglutide) on Ro, your provider can help you determine when to stop, review safer alternatives, and create a plan to manage your weight or blood sugar before conception
In hospitalized patients, blood cultures can reveal widespread bacterial infection, usually from Streptococcus pneumoniae (Sethi 2014)
Coverage depends on the terms of your policy and the insurers medical necessity criteria
Results: The 18-month risk for ION was 8.5 versus 5.5 per 10 000 among GLP-1RA users versus SGLT2i users (RD, 3.0 [95% CI, 0.4 to 5.7]) and 7.8 versus 4.2 per 10 000 among GLP-1RA users versus DPP4i users (RD, 3.6 [CI, 1.1 to 6.1])
RetatrutideMounjaro (Tirzepatide)Wegovy (Semaglutide) Mechanism Triple (GLP-1 + GIP + Glucagon)Dual (GLP-1 + GIP)Single (GLP-1) Best weight loss in trials 30.3%22.5%20.7% Trial duration 104 weeks72 weeks72 weeks UK approval Not yetYes (Mounjaro)Yes (Wegovy) Injection frequency Once weeklyOnce weeklyOnce weekly One important caveat: the 30.3% figure comes from a 104-week trial, while the Mounjaro and Wegovy results are from 72-week trials